兰州地区慢性乙型肝炎病毒基因与干扰素治疗的关系  

Pelationship Between HBV Genotype and Efficacy of α-IFN Therapy Lanzhou

作　　者：邓永东[1] 李文凡[1] 李莹[1] 

机构地区：[1]兰州医学院第一附属医院传染科,兰州730000

出　　处：《临床消化病杂志》2004年第2期51-52,共2页Chinese Journal of Clinical Gastroenterology

摘　　要：目的:观察兰州地区慢性乙型肝炎病毒基因型与干扰素治疗的关系。方法:用套式PCR方法扩增69例经干扰素治疗的慢性乙型肝炎病人的S基因,利用限制性内切酶Sty I和Bsr I平行酶切鉴别乙型肝炎病毒基因型,并追踪其治疗效果。结果:B型19例(27.5％),C型35例(50.7％),D型12例(17.3％)。对于干扰素治疗的应答率,B型与C、D型有显著性差异(p<0.05),C型与D型无显著性差异(P>0.05)。结论:B型病人对干扰素治疗有较好的应答,HBV基因型可能是预测干扰素治疗的因素之一。Objective: The aim of this study to investigate the relationship between hepatitis B virus (HBV) genotype B and efficacy of α-IFN therapy in Lanzhou. Methods: HBV genotypes were classified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). HBV S gene was amplified to 69 serum sample from patient with chronic hepatitis B on α-IFN therapy using nested polymerase chain reaction (nPCR) .The PCR products were digested with two kinds of restriction enzymes Sty I and Bsr I to determine the genotyping of HBV. All patients with α-IFN therapy were follow up for more than 6 months. Results: 69 patients received α-IFN therapy, by PCR-RFLP, HBV from hepatitis B can be divided into three type,i.e.type B,C and D.35(50.7%) sample were classified as genotype C, there were 19(27.5%) and 12(17.3%) cases in patients with genotypes B and C. A-mong 32 reponders to α-IFN therapy, 12 cases was infected with HBV genotype C and 15 patients with genotype B, reponder of genotype D was 4 eases. By statistic analysis, result suggested that the difference was significant in responsive rate to α-IFN therapy between genotype B and genotype C and D (P < 0.05), but genotype C and genotype D have not significant difference in responsive rate to α-IFN therapy (P > 0.05). Conclusion: Chronic hepatitis B patient with genotype B is higher in responsive rate toα-IFN therapy compared with genotype C or D, genotype might be an important predict factor in determining efficacy of α-IFN therapy.

关 键 词：乙型肝炎病毒 基因型 干扰素 

分 类 号：R512.6[医药卫生—内科学]